VN Capital Management
Thornico Holding Tender Offer Substantially Undervalues Company
GREENSBORO, NC / ACCESSWIRE / September 26, 2023 / VN Capital Management LLC, an investment advisor to a fund holding approximately 1.6% of Brødrene Hartmann common shares accumulated since 2021, opposes the recently announced delisting and subsequent tender offer.
VN Capital encourages other minority investors to vote against Brødrene Hartmann's proposed delisting at the company's extraordinary shareholder meeting to be held on Monday, October 16 and to let the Board of Directors know that Thornico Holding's DKK 300 per share offer is unacceptable and drastically undervalues the world's leading egg packaging business.
"Delisting Brødrene Hartmann's shares harms minority investors by depriving them of liquidity and is merely a mechanism designed to eventually force shareholders to sell out to the Stadil family at a cut-rate price, which is especially egregious since many of us would like to remain owners of such a thriving and world-class business.
This related party transaction creates a massive conflict of interest with the Board of Directors. Any attempt to peddle the company out from underneath its minority shareholders for pennies-on-the-dollar will be strongly opposed by us," said James Vanasek, Principal at VN Capital.
"A DKK 300 per share purchase price values the company at a multiple of only 4.9x Enterprise Value to trailing last twelve months EBITDA, the latter of which is temporarily depressed due to unprecedented cost pressures in the company's two main inputs - energy and pulp - that are now abating. Shareholders have shown patience while the company has managed through the Covid-19 pandemic, the disruption due to war in Ukraine, and energy crises afflicting Europe and expect their patience to be rewarded as Hartmann emerges from these challenges. Superlative, best-in-class businesses like Brødrene Hartmann usually trade at 8-10x EV/EBITDA and applying such a multiple to a more normalized earnings level shows that the business is worth twice as much as what the Stadil family if offering to pay for it," added Don Noone, also Principal at VN Capital.
"We have no doubt that if the tables were turned and a competing egg packaging producer offered the Stadils this low-ball price for their shares, the family would not even consider such a bargain basement offer. If the Board of Directors wishes to maximize shareholder value, they should conduct a thorough and robust sales process rather than hand the company over to the Stadils in a sweetheart deal that abandons their fiduciary obligations," said Mr. Noone.
Given this view, VN Capital is exploring all of its legal options in opposition to the proposed delisting and subsequent tender offer and VN Capital encourages other minority shareholders to reject the proposal at the extraordinary shareholder meeting.
It is important to note that a NON-VOTE is effectively a vote in favor of the delisting and tender offer. We urge shareholders who agree with VN Capital's view to not remain passive, but to actively vote NO on the proposals.
About VN Capital Management
VN Capital Management, LLC is a registered investment advisory firm located in New York, New York that was founded in 2002 by P. Donnell Noone and James T. Vanasek. The firm manages a hedge fund that holds a concentrated portfolio of small-cap equities.
About Brødrene Hartmann A/S.
Hartmann is the world's leading manufacturer of moulded-fibre egg packaging and a market-leading manufacturer of fruit packaging in South America and India. The group is also the world's largest manufacturer of technology for the production of moulded-fibre packaging. Founded in 1917, Hartmann is headquartered in Gentofte, Denmark, with a production platform consisting of 15 factories in Europe and Israel, North and South America, India and Russia (discontinuing).
FOR FURTHER INFORMATION PLEASE CONTACT:
VN Capital Management, LLC
Don Noone
+1 (336) 897-1615
pdn@vncapital.net
James Vanasek
+61 407 528 900
jtv@vncapital.net
SOURCE: VN Capital Management
View source version on accesswire.com:
https://www.accesswire.com/787240/brdrene-hartmann-as-investor-urges-shareholders-to-oppose-proposed-delisting-and-subsequent-tender-offer
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Advances Community-Led Forest Protection in Colombia's Meta Region19.11.2025 15:00:00 CET | Press release
New phase of the Sur del Meta Project expands carbon and biodiversity monitoring while strengthening local governance and livelihoods. CALGARY, AB / ACCESS Newswire / November 19, 2025 / In the heart of Colombia's Meta department, where forests and farmlands converge, Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is deepening its commitment to people-powered climate solutions through the REDD+ Sur del Meta Project - a long-term conservation initiative that protects 40,637 hectares of natural forest while supporting sustainable livelihoods for nearly 1,000 local families. Developed through ALLCOT - A Karbon-X Company, the project development and advisory arm of Karbon-X, the initiative operates across the municipalities of Vistahermosa, Puerto Rico, Puerto Concordia, and Puerto Lleras, a region historically affected by deforestation and armed conflict. The project partners with local farmers, many of whom are victims of Colombia's armed conflict, helping them transition from
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom